IP Library › Granted Patent US 12,295,998
Granted Patent B2
US 12,295,998 · App. 18/339,723 · Granted May 13, 2025

Enhancing immunogenicity of

Inventors: Julie M. Skinner (Phoenixville, PA); Patrick McHugh (Pipersville, PA)
Assignee: Merck Sharp & Dohme LLC
A61K39/092A61K39/116A61K47/646A61P31/04A61K2039/6037
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,295,998
App. No.
18/339,723
Granted
May 13, 2025
Kind
B2
Abstract

The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.

Claims (5)

1. A method of preparing a Streptococcus pneumoniae serotype 3 polysaccharide-CRM197 carrier protein conjugate by reductive amination, the method comprising:

a) reacting a Streptococcus pneumoniae serotype 3 polysaccharide with an amount of an oxidant to form an activated Streptococcus pneumoniae serotype 3 polysaccharide; and

b) reacting the activated Streptococcus pneumoniae serotype 3 polysaccharide with a CRM197 carrier protein in dimethylsulfoxide (DMSO) to form a Streptococcus pneumoniae serotype 3 polysaccharide-CRM197 carrier protein conjugate, wherein the lysine loss of the resulting conjugate is greater than 5 moles of lysine per mole of CRM197 carrier protein.

2. The method of claim 1 wherein the lysine loss of the resulting

conjugate is between 7 and 18, moles of lysine per mole of CRM197 carrier protein, inclusive.

Assignments (1)
MERGER Recorded Jun 22, 2023
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 064034/0452 →
Continuity (5)
Continuation 17369177 · Jul 7, 2021
Continuation 16487550
Provisional Application 62555444 · Sep 7, 2017
Provisional Application 62463216 · Feb 24, 2017
Related Publication 20240139303A1 · May 2, 2024
References Cited (70)
US 8192746B2 · Caulfield et al. · 2012 [cited by applicant]
US 8808707B1 · Siber · 2014 [cited by applicant]
US 9669084B2 · Siber · 2017 [cited by applicant]
US 9981029B2 · Park et al. · 2018 [cited by applicant]
US 10406220B2 · Siber et al. · 2019 [cited by applicant]
US 11219680B2 · Macnair · 2022 [cited by applicant]
US 11241489B2 · An · 2022 [cited by applicant]
US 11389540B2 · Porambo · 2022 [cited by applicant]
US 11395849B2 · Porambo · 2022 [cited by applicant]
US 11491216B2 · Porambo · 2022 [cited by applicant]
US 11524076B2 · Porambo · 2022 [cited by applicant]
US 11951165B2 · Fairman · 2024 [cited by applicant]
US 20060263390A1 · Giannozzi et al. · 2006 [cited by applicant]
US 20150202309A1 · Emini et al. · 2015 [cited by applicant]
US 20170021006A1 · Watson et al. · 2017 [cited by applicant]
EP 2932980A1 · 2015 [cited by applicant]
EP 2865392B2 · 2020 [cited by applicant]
WO 2006110352A2 · 2006 [cited by applicant]
WO 2006110381A1 · 2006 [cited by applicant]
WO 2007127665A2 · 2007 [cited by applicant]
WO 2008045852A2 · 2008 [cited by applicant]
WO 2008079653A1 · 2008 [cited by applicant]
WO 2008079732A2 · 2008 [cited by applicant]
WO 2008118752A2 · 2008 [cited by applicant]
WO 2008143709A2 · 2008 [cited by applicant]
WO 2009009629A1 · 2009 [cited by applicant]
WO 2010080484A1 · 2010 [cited by applicant]
WO 2010080486A2 · 2010 [cited by applicant]
WO 2011041003A2 · 2011 [cited by applicant]
WO 2011100151A1 · 2011 [cited by applicant]
WO 2011151760A2 · 2011 [cited by applicant]
WO 2012078482A1 · 2012 [cited by applicant]
WO 2014097099A2 · 2014 [cited by applicant]
WO 2015110940A2 · 2015 [cited by applicant]
WO 2015110941A2 · 2015 [cited by applicant]
WO 2015110942A2 · 2015 [cited by applicant]
WO 2016020499 · 2016 [cited by applicant]
WO 2016113644A1 · 2016 [cited by applicant]
WO 2016178123A1 · 2016 [cited by applicant]
WO 2017013548A1 · 2017 [cited by applicant]
WO 2017085586A1 · 2017 [cited by applicant]
WO 2017085602A1 · 2017 [cited by applicant]
WO 2018027126A1 · 2018 [cited by applicant]
WO 2018126229A2 · 2018 [cited by applicant]
WO 2018134693A1 · 2018 [cited by applicant]
WO 2018144438A1 · 2018 [cited by applicant]
WO 2018144439A1 · 2018 [cited by applicant]
WO 2018156465A1 · 2018 [cited by applicant]
WO 2018156467A1 · 2018 [cited by applicant]
WO 2018156468A1 · 2018 [cited by applicant]
WO 2019036313A1 · 2019 [cited by applicant]
WO 2019050813A1 · 2019 [cited by applicant]
WO 2019050814A1 · 2019 [cited by applicant]
WO 2019050815A1 · 2019 [cited by applicant]
WO 2019050816A1 · 2019 [cited by applicant]
WO 2019050818A1 · 2019 [cited by applicant]
WO 2019083865A1 · 2019 [cited by applicant]
WO 2019139692A2 · 2019 [cited by applicant]
WO 2019212842A1 · 2019 [cited by applicant]
WO 2019212844A1 · 2019 [cited by applicant]
WO 2019212846A1 · 2019 [cited by applicant]
WO 2019236435A1 · 2019 [cited by applicant]
WO 2020121159A1 · 2020 [cited by applicant]
WO 2020131763A2 · 2020 [cited by applicant]
WO 2020208502A1 · 2020 [cited by applicant]
WO 2020247299A1 · 2020 [cited by applicant]
WO 2020247301A1 · 2020 [cited by applicant]
Caro-Aguilar, Ivette et al., Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain, Vaccine, 2017, 865-872, 35(6). [cited by applicant]
Poolman, J.T. et al., The history of pneumococcal conjugate vaccine development: dose selection, Expert Review of Vaccines, 2013, 1379-1394, 12:12. [cited by applicant]
Skinner et al., Pre-clinical Evaluation of a 15-Valent Pneumococcal Conjugate Vaccine (PCV15-CRM197) In an Infant-Rhesus Monkey Immunogenicity Model, Vaccine, 2011, 8870-8876, 29. [cited by applicant]